On March 1, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) share price continued the strength of the previous trading day and rose all the way after the opening. As of the closing, it closed at 163.02 yuan / share, an increase of 20%, and the market value exceeded 20 billion yuan for the first time.
In October 2021, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) officially landed in a shares. After listing, its share price once rose to 120.03 yuan / share in a short time, and then showed a downward trend. It rebounded sharply after mid January 2022. Data show that Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) share price has risen by 514.94% since its listing.
According to the data of pharmaceutical network, China needs more than 2000 kinds of raw materials and intermediates supporting chemical industry every year, with a demand of more than 2.5 million tons. With the progress of medicine, especially the covid-19 epidemic continues, the market scale of China Meheco Group Co.Ltd(600056) intermediate will continue to expand.
Zhao Hui, stock analyst of Tibet Jinxiu commodity exchange, said in an interview with the reporter of Securities Daily: "At present, Omicron strain has replaced delta strain as the main epidemic strain in the world, and 98.3% of the recently reported sequences in various regions are Omicron strain. With the continuation of covid-19 epidemic, there will be continued demand for small molecule antiviral drugs, vaccine booster and other related products. Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) has advantages in the field of API and intermediate upstream of finished drugs."
The key raw material for the production of polymerase preparations is nucleoside (acid). In the field of nucleoside (acid) APIs and pharmaceutical intermediates in China, Xinxiang Tuoxin Pharmaceutical Co.Ltd(301089) has a leading position and has formed a relatively complete product chain from basic products to high-end products.
